Detox While Pregnant: What the Guidelines Say for Opioids, Alcohol, and Benzodiazepines

Can you detox while pregnant?

It depends on the drug, and for opioids the answer runs against instinct.

For opioids, the recommended treatment in pregnancy is not detox. It is methadone or buprenorphine, started as early in pregnancy as possible. For alcohol, withdrawal has to be managed under medical care, with inpatient treatment considered and an obstetrician involved. For benzodiazepines, the first rule is no sudden stop.

Wanting every drug out of your body before the baby arrives is a reasonable instinct. With opioids, acting on it can put both of you at risk.

Why opioid detox is not recommended in pregnancy

The CDC and two medical societies reach the same conclusion. The CDC says that for pregnant women with opioid use disorder, medication is preferred over withdrawal management by tapering, and that there are possible risks to both the woman and the fetus if she goes into withdrawal. ASAM’s 2020 guideline says pregnant women who are physically dependent on opioids should be treated with methadone or buprenorphine rather than withdrawal management or counseling alone. The ACOG and ASAM committee opinion calls opioid agonist medication the recommended therapy and says withdrawal is associated with high relapse rates.

Relapse is where the danger sits. Opioid withdrawal is rarely fatal by itself, though tolerance falls within days, so a return to a former dose can be fatal. In New Jersey’s fentanyl supply, nobody can know what a former dose even is.

The same committee opinion leaves one door open: if a patient declines medication or it is not available, medically supervised withdrawal can be considered, under a physician experienced in perinatal addiction treatment and with her informed consent. That is a supervised exception. It is not quitting on your own.

What not to do

• Do not stop opioids suddenly on your own.
• Do not start buprenorphine on your own after fentanyl; see precipitated withdrawal.
• Do not wait for a prenatal visit weeks away. Programs that serve women and are funded by the state’s block grant must give pregnant women priority; see below.

Methadone in pregnancy

Methadone is given through opioid treatment programs. ASAM’s 2020 guideline adds a few pregnancy-specific points worth knowing before the first visit:

• Starting methadone or buprenorphine in a hospital may be advisable, especially in the third trimester.
• As pregnancy goes on, methadone levels in the blood fall and the body clears it faster, so higher or split doses may be needed. Twice-daily dosing works better but may not be practical at a clinic.
• After birth, the dose may need to be adjusted, typically down.
• Care should be shared by a clinician experienced in obstetrics and one experienced in treating opioid use disorder.

The committee opinion makes the same point about the third trimester and adds that not every woman needs a dose increase. A dose that worked early in pregnancy may stop holding later. Say so when it happens; that is pregnancy changing how methadone works, not a failure.

Buprenorphine in pregnancy

Since the 2023 removal of the federal X-waiver, any prescriber whose DEA registration covers Schedule III can prescribe buprenorphine, so it can be started in an office visit. Older guidance preferred the buprenorphine-only product in pregnancy. The ACOG and ASAM opinion notes that studies of the buprenorphine-naloxone combination found no adverse effects, and ACOG’s 2025 clinical practice update says clinicians can prescribe buprenorphine alone or in combination with naloxone. Our Suboxone, Subutex and Sublocade guide covers the forms.

If you become pregnant while taking naltrexone, ASAM says stopping it may be appropriate if you and the clinician agree the risk of relapse is low; if that risk is real, methadone or buprenorphine should be considered.

Will my baby go through withdrawal?

Possibly, and it is treatable. The ACOG and ASAM opinion calls neonatal abstinence syndrome “an expected and treatable condition” seen in 30 to 80 percent of babies born to women taking opioid agonist medication. The opinion’s summary says babies exposed to opioids should be monitored for it by a pediatric provider. The CDC advises planning delivery at a hospital that can monitor and treat newborn withdrawal; ask yours early.

Breastfeeding is encouraged for many. ASAM says mothers on methadone or buprenorphine should be encouraged to breastfeed unless something else rules it out, and the committee opinion adds the condition that the mother is stable and not using illicit drugs.

Alcohol withdrawal during pregnancy

Alcohol is different: there is no substitute medication to keep taking, so withdrawal has to be managed. The ASAM alcohol withdrawal guideline is specific:

• Inpatient treatment should be considered for every pregnant patient who needs alcohol withdrawal management, and offered to anyone with at least moderate withdrawal (a CIWA-Ar score of 10 or higher).
• An obstetrician should be consulted. Fetal monitoring may be warranted because of the risk of placental abruption, preterm delivery, and fetal distress or death.
• Benzodiazepines and barbiturates are the medications of choice. The guideline says the first-trimester risk appears small and is outweighed by the risks of fetal alcohol spectrum disorder and severe maternal withdrawal.
• Valproic acid is not recommended in pregnancy.
• Late in pregnancy, a short-acting benzodiazepine is preferred, and a baby born soon after should be checked for sedation and withdrawal.

The guideline also tells clinicians to treat nausea, headache, anxiety, and insomnia in a pregnant patient as withdrawal symptoms that will ease with treatment, not as ordinary pregnancy discomfort. Our alcohol withdrawal timeline covers how withdrawal unfolds.

Benzodiazepines during pregnancy

Do not stop a benzodiazepine suddenly because you found out you are pregnant. The Xanax label warns that stopping abruptly or cutting the dose quickly after continued use can cause withdrawal reactions that can be life-threatening, and calls for a gradual taper.

The label also says use late in pregnancy can leave a newborn sedated or in withdrawal, and that published observational studies do not show a clear link to major birth defects. Those two facts point the same way: the plan belongs to the prescriber and the obstetrician together. Our Xanax withdrawal guide covers tapering.

After the baby is born

The months after birth carry their own risk. The committee opinion says women with opioid use disorder relapse far more often after delivery than during pregnancy, and that postpartum women with opioid use disorder should receive overdose training. Staying on medication matters here. Pooled cohort studies in the BMJ (Sordo, 2017) and JAMA Psychiatry (Santo, 2021) found all-cause death rates about half as high or lower during time on methadone or buprenorphine than during time off them.

Keep naloxone at home and make sure another adult knows where it is. Our naloxone guide for families covers how to get it in New Jersey.

Will asking for help mean child protective services?

Getting treatment does not take a baby outside New Jersey’s newborn rules. Hospitals must notify the Division of Child Protection and Permanency (DCP&P) about newborns affected by substance use or drug withdrawal, and that includes a baby in withdrawal from methadone or buprenorphine that was prescribed. A notification is not by itself an allegation of abuse or neglect. DCP&P first decides whether it is one. If it is, DCP&P policy calls for a caseworker to begin an investigation before the baby leaves the hospital. If it is not, the division offers the family services on a voluntary basis. DCP&P policy also calls for a Family Care Plan for each substance-affected newborn referred to it, covering services for the parents and the baby, safe sleep, car seat safety, and safe storage of medicine.

Treatment helps on both sides of that process. According to the state’s Division of Mental Health and Addiction Services, contracts for women’s treatment and its pregnant and parenting programs require a Plan of Safe Care for pregnant and postpartum clients, built before birth whenever possible, to coordinate services for the mother, the baby, and the family. DCP&P policy says its caseworker reviews and updates a plan the family already has.

Then there is a 2014 ruling. The New Jersey Supreme Court held that, absent exceptional circumstances, a finding of abuse or neglect cannot rest solely on a newborn’s methadone withdrawal when the mother took part in a bona fide treatment program prescribed by a licensed professional to whom she made full disclosure.

That is not a promise about any one case, and this is not legal advice. It is a reason the treatment path is also the safer path. ASAM says laws that penalize women for substance use and for getting treatment keep them from prenatal care and worsen outcomes, and ACOG says an approach without criminal sanctions has the best chance of helping infants and families.

Help for pregnant people in New Jersey

• Priority admission. Under federal rules for programs funded by the state’s substance use block grant, 45 CFR 96.131, programs that serve women must give pregnant women preference in admission, and a program without room must refer them to the state. New Jersey requires the treatment agencies in its fee-for-service network to offer pregnant and parenting clients interim services, including case management, referrals, and medication if needed, within 48 hours while they wait for admission.
• Maternal Wraparound Program (M-WRAP). A DMHAS program of intensive case management, wraparound services, and peer recovery support for people with a substance use disorder, during pregnancy and up to one year after birth.
• Integrated Opioid Treatment and Substance Exposed Infants (IOT-SEI). Five state-funded programs that combine prenatal and obstetric care, opioid treatment including medication, newborn care, and case management for pregnant women with opioid use disorder.
• NJ FamilyCare in pregnancy. The state lists coverage for pregnant women with family income at or below 205 percent of the federal poverty level who are U.S. citizens or lawfully present immigrants, and lists other programs for prenatal care, emergency care including labor and delivery, and hospital bills.

Ask for M-WRAP and IOT-SEI by name when you call the IME or ReachNJ, and say “I am pregnant” in the first sentence so the program can apply the priority rules.

In New Jersey

Under New Jersey law P.L.2017, c.28, fully insured New Jersey plans and the State Health Benefits and School Employees’ plans cannot require prior authorization for the first 180 days per plan year of in-network treatment your own physician, psychologist or psychiatrist finds medically necessary, or, during those same 180 days, for outpatient prescription drugs that treat substance use disorder, such as buprenorphine and naltrexone, when that clinician finds them medically necessary. Self-funded employer plans, Medicare and Medicaid are not covered by that rule, so verify with the plan.

NJ FamilyCare covers buprenorphine, methadone, and naltrexone. Residential detox is authorized through the IME for most members, and residential care and opioid treatment programs are scheduled to move into the NJ FamilyCare health plans in January 2027. The opioid detox guide and the alcohol detox guide list New Jersey’s licensed programs.

For help independent of us, the state’s IME Addictions Access Center at 1-844-276-2777 screens NJ FamilyCare and uninsured residents and refers them to treatment, and ReachNJ, the state treatment line, is at 1-844-732-2465. Periscope Behavioral Health, which publishes this site, is opening a medical detox in Hammonton, Atlantic County, expected Summer 2027. Until it opens, Periscope Behavioral Health at (888) 313-3583, our publisher’s admissions line, can talk through options in New Jersey and Florida, including facilities Periscope operates. What a plan covers depends on the plan and the facility’s network status.

What to say on the first call

1. “I am pregnant,” and how many weeks.
2. What you use, how much, and when you last used it, including alcohol, pills, and anything you are unsure about.
3. Whether you are already on methadone, buprenorphine, or naltrexone.
4. Who your prenatal provider is, or that you do not have one yet.

You do not need any of this worked out before you call. If all you can say at first is “I am pregnant and I am using,” that is enough to start.